• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

4.770 +0.330 (+7.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 253,332
Open 4.330
Bid (Size) 4.700 (1)
Ask (Size) 4.840 (2)
Prev. Close 4.440
Today's Range 4.054 - 4.900
52wk Range 2.550 - 6.118
Shares Outstanding 10,784,725
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan
July 31, 2025
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300
July 31, 2025
From Lantern Pharma Inc.
Via Business Wire

Performance

YTD
+44.5%
+44.5%
1 Month
+46.8%
+46.8%
3 Month
+30.0%
+30.0%
6 Month
+2.1%
+2.1%
1 Year
+27.5%
+27.5%

More News

Read More
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology
July 28, 2025
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors
July 28, 2025
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
July 25, 2025
Via ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL
July 23, 2025
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
July 23, 2025
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284
July 21, 2025
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
July 21, 2025
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Taps IBN to Lead Corporate Communications Amid AI-Driven Oncology Pipeline Progress
July 16, 2025
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies
July 15, 2025
Via Investor Brand Network
Topics Artificial Intelligence
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies
July 15, 2025
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
July 15, 2025
From Lantern Pharma Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
July 08, 2025
Via Benzinga
AINewsBreaks – Why Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’
June 30, 2025
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial
June 26, 2025
Via Investor Brand Network
Topics Artificial Intelligence
InvestorNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial
June 16, 2025
Via Investor Brand Network
Topics Artificial Intelligence
Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years
June 16, 2025
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’
June 11, 2025
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Panna Sharma, Lantern Pharma CEO, Says FDA’s Elsa AI Rollout Underscores Urgency to Modernize
June 09, 2025
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Highlights LP-184 Preclinical Success in Pediatric Brain Cancer ATRT
May 30, 2025
Via Investor Brand Network
Topics Artificial Intelligence
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials
May 29, 2025
From Lantern Pharma Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 22, 2025
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 16, 2025
Via Benzinga
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
May 15, 2025
From Lantern Pharma Inc.
Via Business Wire

Frequently Asked Questions

Is Lantern Pharma Inc. - Common Stock publicly traded?
Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
What exchange does Lantern Pharma Inc. - Common Stock trade on?
Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
What is the current price of Lantern Pharma Inc. - Common Stock?
The current price of Lantern Pharma Inc. - Common Stock is 4.770
When was Lantern Pharma Inc. - Common Stock last traded?
The last trade of Lantern Pharma Inc. - Common Stock was at 08/01/25 04:00 PM ET
What is the market capitalization of Lantern Pharma Inc. - Common Stock?
The market capitalization of Lantern Pharma Inc. - Common Stock is 51.44M
How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
Lantern Pharma Inc. - Common Stock has 51M shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap